Sanofi-Aventis Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Sanofi-Aventis (formerly Sanofi-Synthelabo) on December 20, 2004. The filing serves to incorporate by reference a press release issued on the same date regarding a specific intellectual property development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material event disclosed is the issuance of a Notice of Allowance by the U.S. Patent Office regarding Aventis's reissuance application for the Lovenox(R) `618 patent. This represents a significant development in the company's intellectual property portfolio for the Lovenox product line.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of general risks and contingencies. The focus is strictly on the patent allowance status.
Key Facts for Investor Verification
- U.S. Patent Office issued a Notice of Allowance for the Lovenox(R) `618 patent reissuance application.
- The filing incorporates a press release dated December 20, 2004, as Exhibit 99.1.
- No financial performance data is included in this specific filing.